MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL

• Published in: International journal of cancer 2012-05, Vol.130 (9), p.2054-2061
• Main Authors: Dong, Hua-Jie, Fang, Cheng, Fan, Lei, Zhu, Dan-Xia, Wang, Dong-Mei, Zhu, Hua-Yuan, Zhuang, Yun, Miao, Kou-Rong, Liu, Peng, Xu, Wei, Li, Jian-Yong
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Biological and medical sciences; Cancer; Chromosome Aberrations; chronic lymphocytic leukemia; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Genes; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Genotype & phenotype; Hematologic and hematopoietic diseases; Heterozygote; Humans; Kaplan-Meier Estimate; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell - genetics; Leukemia, Lymphocytic, Chronic, B-Cell - pathology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; MDM2; Medical research; Medical sciences; Middle Aged; Polymorphism, Single Nucleotide - genetics; Promoter Regions, Genetic; Proto-Oncogene Proteins c-mdm2 - genetics; Risk Factors; RNA, Messenger - genetics; Sequence Deletion; SNP; Survival analysis; Tumor Suppressor Protein p53 - genetics; Tumors
• ISSN: 0020-7136; 1097-0215
• DOI: 10.1002/ijc.26222

A single nucleotide polymorphism (SNP) at position 309 in the promoter region of MDM2 leading to increased expression of MDM2 and attenuated function of p53 has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this has been questioned. The MDM2 SNP309 genotypes in 173 CLL patients and 260 healthy controls were detected by the polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP) method, which was confirmed by direct DNA sequencing. Compared with the T/T genotype, the SNP309 G/G genotype instead of T/G heterozygote was associated with a significantly increased risk of CLL (OR = 2.84; 95% CI 1.61–5.03; p < 0.001). Age at onset of CLL was similar irrespective of MDM2 status. MDM2 mRNA expression within CLL of G/G genotype was significantly higher than that in T/G (p = 0.009) and T/T genotypes (p < 0.001). Excluding patients with p53 deletions or mutations enhanced the significance of the findings (G/G vs. T/T, p < 0.001; G/G vs. T/G p = 0.001), which prompted us to study the role of the polymorphism in p53 wild‐type individuals. In the p53 wild‐type groups, survival analysis showed that the patients with MDM2 SNP309 G/G and T/G genotypes both had significantly shorter treatment‐free survival (TFS) than SNP309 T/T genotype. Notably, univariate and multivariate analyses showed that MDM2 SNP309 genotypes were associated with TFS. These data show that MDM2 309G polymorphisms contribute to the risk of developing CLL. The unfavorable MDM2 SNP309 G/G genotype was associated with an increase of MDM2 mRNA expression. MDM2 SNP309 was found to be associated with TFS in p53 wild‐type Chinese CLL populations.